GlassScriptPhysician profile
Jamie M Leonard
NPI 1013455724
$2,146.58
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $375 · 2023: $459 · 2024: $672 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.22 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $252.63 | 2022-2025 | |
| Abbvie INC. | $240.08 | 2023-2025 | |
| Dexcom, INC. | $238.20 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $187.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $185.55 | 2023-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $166.37 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $128.32 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $90.82 | 2021-2022 | |
| Boston Scientific Corporation | $86.78 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $84.28 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $83.90 | 2022-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.38 | 2021-2024 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $73.99 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $58.23 | 2023-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $32.74 | 2021-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.73 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.48 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $18.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.93 | 2022 | |
| Tandem Diabetes Care, INC. | $16.91 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Medtronic, INC. | $14.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.58 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.